Dasatinib Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Dasatinib dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Dasatinib.
Dosing Protocols
IMPORTANT: Dasatinib is a prescription medication with a substantial side effect profile. Use for any indication — including senolytic applications — requires physician prescription, partnership, and monitoring. The "beginner protocol" described here is for educational orientation only; actual use must be physician-guided. Beginner Educational Orientation: For individuals new to senolytic concepts considering dasatinib-based approach: Step 1 — Consider Fisetin First: Fisetin 1000-2000 mg/day × 2-3 consecutive days monthly is a much safer entry point to senolytic approaches. OTC, minimal side effects, no prescription required, emerging evidence base. For most people interested in senolytic interventions, fisetin is the appropriate first approach. Proceed to dasatinib only if there is specific rationale for more potent intervention. Step 2 — Establish Physician Partnership: Dasatinib requires prescription. Partnership with a physician familiar with senolytic medicine is essential. Sources: longevity medicine specialists, functional medicine physicians with senolytic experience, research clinics with senolytic trial programs, some integrative oncology practices. Random physicians unfamiliar with senolytic medicine will not prescribe dasatinib off-label; expect to invest in finding appropriate partnership. Step 3 — Baseline Evaluation: Before any dasatinib exposure, comprehensive baseline assessment: Complete blood count (CBC); Comprehensive metabolic panel (CMP) including liver enzymes; Coagulation studies (PT/INR, aPTT) if indicated; ECG (for baseline QTc); Echocardiogram (for baseline pulmonary pressure if long-term use anticipated); Medication review with pharmacist for drug interactions (PPI history, CYP3A4 interactions); Screening for hepatitis B (HBsAg, anti-HBc); Discussion of bleeding history, cardiovascular history, pulmonary history; Informed consent documentation. Step 4 — First Pulse Preparation: Identify the specific intended indication and rationale. Most common entry scenarios: Age-related frailty with elevated inflammation; Specific senescence-driven condition (OA, IPF, DKD); Longevity optimization in older adults (>55) with comprehensive healthspan-oriented care. Discuss dosing schedule: most commonly 100 mg once daily × 2 consecutive days, with first-time users often starting with single 100 mg dose to assess tolerance. Some physicians prefer 50 mg × 2 days for first exposure. Combine with quercetin 1000 mg × 2-3 days (matched schedule) for D+Q protocol. Step 5 — Medication Review Before First Pulse: Hold or time-separate any CYP3A4 inhibitors (antifungals, macrolides, grapefruit products); Hold or time-separate PPIs (use H2 blocker alternative with timing separation if acid reduction needed); Hold NSAIDs for several days before and after pulse; Hold antiplatelet agents (aspirin, clopidogrel) during pulse days per physician guidance; Review all supplements for bleeding-risk compounds (ginkgo, high-dose fish oil, high-dose vitamin E); Ensure no planned invasive procedures or dental work during or shortly after pulse. Step 6 — First Pulse Day: Take dasatinib 100 mg in morning with or without food; Take quercetin 1000 mg concurrently; Monitor for acute adverse effects (rare within first day); Maintain normal activity level; Avoid alcohol; Stay well-hydrated; Note any symptoms for discussion with physician. Step 7 — Second Pulse Day (if 2-day protocol): Same medication timing as day 1; Continue monitoring. Step 8 — Post-Pulse Monitoring: Watch for symptoms over 1-2 weeks post-pulse: Unusual bleeding or bruising (GI, nosebleeds, urinary, gum); Severe fatigue beyond expected transient fatigue; Chest pain, shortness of breath (cardiac/pulmonary concerns); Severe GI symptoms; Significant headache; Edema or rapid weight gain. Any significant symptom warrants medical evaluation. Repeat CBC at 1-2 weeks to confirm no unexpected cytopenia. Step 9 — Response Assessment at 1 Month: Subjective: energy, function, pain, cognitive sharpness, sleep quality. Physical: functional tests if baseline obtained (6-minute walk, grip strength, balance). Biomarkers: inflammatory markers (hs-CRP, IL-6) if tracked. Indication-specific outcomes. Decision point: proceed with subsequent cycles, adjust protocol, or discontinue. Step 10 — Ongoing Protocol: If tolerated and perceived benefit: D+Q cycles monthly or every 2-3 months, depending on individual response and physician guidance. Continued monitoring at each cycle. Annual comprehensive health assessment. Red Flag Scenarios Requiring Immediate Medical Attention: Hematemesis, hematochezia, melena (GI bleeding); Prolonged or heavy bleeding from any site; Severe unexplained shortness of breath or chest pain; Severe persistent headache with visual changes or neurologic symptoms; Significant peripheral edema or sudden weight gain >3 lb/day (fluid retention); Rapid heart rate, palpitations; High fever or signs of infection (possible myelosuppression-related); Severe persistent GI symptoms; Jaundice or signs of hepatitis. Cost Considerations: Brand Sprycel 100 mg tablets historically $300+/tablet; generic dasatinib now available, cost varies. Typical senolytic protocol: 2-3 tablets × 6-12 cycles/year = ~$2,000-$20,000/year depending on pharmacy and insurance (many pharmacies offer generic dasatinib substantially below brand pricing). Quercetin: OTC, $15-30/month equivalent for cycles. Product Selection: Use prescription generic or brand dasatinib from licensed pharmacy. Do NOT use research-chemical-sourced material (quality unreliable, legally problematic). Quercetin options: standard quercetin dihydrate 500 mg capsules ($15-25/bottle of 100); quercetin phytosome (Quercefit or SR-Quercetin; better bioavailability; more expensive); quercetin with piperine or other enhancers. Choose reputable brands. Realistic Expectations: Senolytic effects in humans are emerging. The strongest trial data (Justice 2019, Hickson 2019) show biomarker changes and modest functional improvements, not dramatic transformations. Multiple cycles may be needed to see cumulative benefit. Individual response varies substantially. Not a "fountain of youth" — an investigational approach with promising but limited evidence base.
Intermediate dasatinib senolytic protocols assume established physician partnership, completed baseline evaluation and first-pulse safety check, and clear indication/rationale. Users at this level are refining dosing schedule, adding complementary interventions, and tracking response. Pulse Schedule Optimization: Standard schedules: Monthly: D+Q for 2 consecutive days once monthly. Most aggressive senolytic schedule. Reasonable for: high senescent cell burden contexts (significant frailty, multiple age-related dysfunctions), specific disease indications with strong senescent cell contribution (OA flares, metabolic syndrome with inflammation). Every 6-8 Weeks: D+Q for 2 consecutive days every 6-8 weeks. Moderate schedule. Reasonable for: general longevity optimization in older adults, maintenance after initial response. Quarterly (Every 3 Months): D+Q for 2-3 consecutive days every 3 months. Conservative maintenance schedule. Reasonable for: long-term maintenance, lower senescent cell burden, older patients where frequent treatment toxicity is concerning. Individualized based on biomarkers: Some practitioners dose based on inflammatory markers — treat when hs-CRP rises above threshold, observed monthly-quarterly. Dose Optimization: Standard dose: Dasatinib 100 mg + Quercetin 1000 mg × 2-3 consecutive days. Dose Reduction for Sensitivity: Dasatinib 50 mg or 70 mg + Quercetin 500-1000 mg for patients with smaller body size, prior tolerability issues, or elderly frail patients. Split Dosing Day (uncommon): Some practitioners use dasatinib 50 mg AM + 50 mg PM instead of single 100 mg dose for better tolerability; rationale for pharmacokinetic smoothing. Duration: 2 consecutive days is the most common protocol. Some protocols use 3 consecutive days (as in Justice 2019 and Hickson 2019). Longer consecutive dosing increases cumulative exposure; not clearly needed. Integrating with Overall Longevity Stack: Chronic daily components (run through all cycles): Metformin 500 mg BID, Berberine 500 mg BID, NAC 600 mg BID, NMN 500-1000 mg/day, CoQ10 100-200 mg/day, Omega-3 EPA/DHA 2-3 g/day, Vitamin D 4000 IU/day, Vitamin K2 100-200 mcg/day, Magnesium Glycinate 400-600 mg/day, Creatine 5 g/day, B-complex methylated, Curcumin enhanced formulation 500 mg/day. Pulsed senolytic component: D+Q on schedule as above. Cycled components: Rapamycin weekly 3-6 mg (if used); Fisetin cycles alternating with D+Q or adjunctive. Rapamycin + D+Q Coordination: Rapamycin weekly and D+Q pulsed are mechanistically complementary. Schedule considerations: avoid dasatinib and rapamycin on same day (additive CYP3A4 burden, theoretical QTc concerns); typical approach is rapamycin weekly on fixed day (e.g., Sunday), D+Q pulses separated by at least 2 days from rapamycin dose. Requires physician guidance for polypharmacy coordination. Fisetin Alternation: Some protocols alternate D+Q cycles with fisetin cycles, maintaining continuous senolytic pressure while rotating mechanism: Month 1: D+Q × 2 days. Month 2: Fisetin × 2 days. Month 3: D+Q × 2 days. Etc. Mechanistic rationale: different senolytic spectra. Evidence-level preliminary. Monitoring Cadence: Every Pulse: Post-pulse symptom review, CBC at 1-2 weeks post-pulse for first 2-3 cycles then less frequently. Every 3-6 Months: Comprehensive metabolic panel, CBC, hs-CRP, inflammatory markers. Annually: ECG, functional assessments, imaging per clinical indication, comprehensive medication review, risk-benefit reassessment for continued treatment. Response Tracking: Multiple domains: Subjective well-being, energy, cognitive sharpness; Physical function (6-minute walk, grip strength, chair stands, balance tests); Inflammatory markers (hs-CRP, IL-6, TNF-α); Metabolic markers (HbA1c, lipids, fasting insulin); Body composition; Indication-specific markers (joint function for OA, respiratory function for IPF, renal function for DKD); Quality of life measures. Track in journal or formal tool. Response Patterns: Common: Gradual improvement in function and energy over 3-6 cycles (months); Reduction in inflammatory markers; Improved sleep quality; Reduced joint/musculoskeletal discomfort; Reduced specific inflammatory-driven symptoms. No Response at 6 Cycles: Consider: protocol adjustment (dose, frequency, alternative senolytic); evaluation for other contributing factors (ongoing inflammation sources, nutritional deficiencies, other medical conditions); discontinuation if risk-benefit not favorable. Adverse Events and Adjustments: Any significant adverse event: immediate hold of further cycles pending evaluation. Persistent mild adverse effects: dose reduction or schedule extension (e.g., quarterly instead of monthly). Specific concerns: Fluid retention → consider schedule reduction or discontinuation if persistent; Bleeding events → thorough evaluation; GI symptoms → dietary/supplement adjustments; Fatigue → hydration, nutrition, gradual return to activity. Lifestyle Amplifiers: Exercise programming: regular resistance training 2-3x/week + aerobic 150 min/week. Exercise-induced beneficial cellular responses complement senolytic effects. Nutrition: Mediterranean/anti-inflammatory diet pattern; adequate protein (1.2-1.6 g/kg for older adults); adequate micronutrients. Sleep: 7-9 hours; regular schedule; sleep apnea screening if symptoms. Stress management: meditation, yoga, nature exposure, social connection. These lifestyle factors have larger effect sizes than any pharmacologic senolytic intervention. Medication List Management: Maintain current comprehensive medication list; update with all prescribers; review for interactions with each new medication; particular attention to CYP3A4 substrates/inhibitors/inducers; particular attention to gastric acid modifiers. Travel Considerations: Dasatinib is prescription; travel with official prescription documentation; original pharmacy container; quercetin is OTC, no restrictions. Emergency Considerations: Wear medical alert identification if long-term dasatinib use. Inform ED providers of recent dasatinib exposure; particular relevance in trauma (bleeding), cardiac (QTc/arrhythmia), or respiratory emergencies. Age Considerations: Most senolytic candidates are older adults (>55). Frail elderly may benefit but tolerate side effects less well — lower doses, longer intervals. Young adults (<40) generally do not have substantial senescent cell burden to warrant senolytic treatment; consider whether other interventions would be more appropriate. Comorbidity Considerations: Diabetes: compatible; may help via adipose senescence reduction. Hypertension: compatible; monitor BP during pulses. Cardiovascular disease: caution; review with cardiology. Pulmonary disease: caution; review with pulmonology given pleural effusion concern. Renal disease: generally compatible; DKD is potential indication. Hepatic disease: caution given metabolism. Bleeding disorders: relative contraindication. Cancer history: coordinate with oncology. Discontinuation: Can be stopped anytime without withdrawal effects. Senescent cell burden gradually recovers over months post-discontinuation. Some practitioners use finite treatment courses (e.g., 12 cycles) then discontinue and reassess; others use ongoing maintenance. No clear evidence basis for either approach.
Advanced dasatinib senolytic protocols address complex clinical scenarios, combination approaches with multiple interventions, and cutting-edge applications. These protocols require experienced physician partnership and typically involve comprehensive longevity medicine practices, research settings, or specific disease contexts. Aggressive Senolytic Protocol for High Senescent Burden: Indications: Significant frailty; multiple age-related conditions; high inflammatory markers; post-chemotherapy/radiation recovery; post-severe illness recovery. Protocol: D+Q every 4 weeks × 6-12 cycles (6-12 months), then reassess and transition to maintenance. May combine with fisetin intercycle: D+Q on week 1; fisetin on week 3; repeat monthly cycle. Requires intensive monitoring given higher cumulative exposure. Specific Disease-Directed Senolytic Protocols: Idiopathic Pulmonary Fibrosis (Justice 2019 evolved): D+Q daily × 3 consecutive days per week × 3 weeks (9 total treatment days in 3-week period). Repeat quarterly. Requires pulmonology coordination. Diabetic Kidney Disease: D+Q × 3 consecutive days; repeat every 3-6 months based on renal trajectory and biomarkers. Nephrology coordination. Osteoarthritis (Severe, Refractory): D+Q × 2-3 days monthly or quarterly; combine with intra-articular interventions (HA, PRP, BMAC) for comprehensive joint-preservation approach. Post-Cancer Treatment Senescence: D+Q × 2-3 days initiated 4-12 weeks post-cancer treatment completion; monthly × 6-12 cycles during recovery period; coordinate with oncology. Frailty in Older Adults: D+Q × 2 days every 6-8 weeks; coordinate with comprehensive geriatric assessment and targeted interventions (resistance training, protein nutrition, fall prevention). Comprehensive Longevity Protocol (Advanced): Daily chronic: Metformin 1500 mg/day; NMN 1000 mg/day; NAC 1200 mg/day; CoQ10 Ubiquinol 200 mg/day; Berberine 500 mg TID; Curcumin enhanced 1000 mg/day; Omega-3 EPA/DHA 3-4 g/day; Vitamin D 5000 IU + K2 200 mcg; Magnesium 600 mg; Creatine 5 g; B-complex methylated; targeted additions per individual assessment. Pulsed: D+Q × 2-3 days monthly OR alternating D+Q/fisetin; Rapamycin weekly 4-6 mg (or per physician protocol); optional additional pulsed interventions (e.g., methylene blue cycles, spermidine courses). Lifestyle foundation: intensive exercise programming; whole foods anti-inflammatory diet; optimal sleep hygiene; stress management; social/cognitive engagement. Comprehensive monitoring: quarterly basic labs; annual comprehensive panel including inflammatory markers, metabolic markers, hormones, micronutrients; biennial imaging/functional assessments; ongoing clinical review. Clinical Research Participation: For patients interested in advanced protocols, clinical trial enrollment is optimal path: access to senolytic interventions in regulated settings; comprehensive monitoring; contribution to evidence base; potentially earlier access to novel senolytics beyond D+Q. ClinicalTrials.gov and Mayo Clinic Kogod Center for Aging maintain trial listings. Dasatinib Alternatives in Senolytic Class: As evidence accumulates, other senolytics become available: Navitoclax (ABT-263): broader BCL-2 family inhibitor; more potent senolytic but worse hematologic toxicity; primarily in clinical trials. UBX1325: intravitreal senolytic for AMD/DR; specific indication. Fisetin: natural flavonoid, OTC, much better safety — preferred entry-level senolytic for most patients. Proxofim (FOXO4-DRI): peptide senolytic in preclinical/early clinical development; targets FOXO4-p53 interaction. Different mechanism than D+Q. Piperlongumine: emerging natural senolytic; limited clinical evidence. Cardiac glycosides (digoxin, ouabain): recently identified senolytic class at low doses; active clinical development. Next-generation targeted senolytics: various developmental-stage agents with specific senescent-cell targeting. Landscape evolving rapidly through 2026-2030. Combining Multiple Senolytics: Research-level. Sequential rotation (D+Q → fisetin → other senolytic over cycles) is intuitive but not validated. Simultaneous multi-senolytic is not standard; toxicity concerns. Current practice is typically single senolytic per cycle, with rotation over longer timescales. Advanced Monitoring: Beyond routine labs, advanced practitioners may incorporate: Senescence-specific biomarkers: p16INK4a expression in peripheral blood mononuclear cells (PBMCs; research assay); telomere length; specific SASP factor panels. Epigenetic age clocks: DunedinPACE, GrimAge, Horvath clock, PhenoAge (methylation-based). May be tracked pre/post senolytic intervention to assess biological age effects. Evidence for senolytic effects on these measures is emerging. Organ-specific senescence: e.g., adipose biopsy for senescence markers (as in Hickson 2019); less common in routine practice. Functional aging markers: grip strength, gait speed, chair stands, balance; VO2max; bone density. Cardiovascular aging: arterial stiffness, coronary calcium score, endothelial function. Inflammation markers: hs-CRP, IL-6, TNF-α; advanced cytokine panels. Integration with Regenerative Medicine: Some practitioners combine senolytic treatment with regenerative approaches: stem cell therapy (autologous/allogeneic); PRP/growth factor therapy; exosome therapy; tissue-specific regenerative interventions. Rationale: senolytic clearance creates "space" for regenerative/stem cell activity. Evidence level preliminary; research in specific indications (OA, neurodegeneration, cardiac regeneration). Genetic/Genomic Considerations: Some advanced practices incorporate genetic profiling: CYP3A4 variants affecting dasatinib metabolism; SCAP-related gene variants potentially affecting senolytic response; telomere biology genes; lamin A variants (progeroid syndromes). Clinical utility of these is emerging. Disease-Prevention Senolytic Programs: Use of senolytics before symptomatic disease onset — primary prevention framework. Rationale: clear senescent cells before they accumulate to disease-driving levels. Evidence level preliminary; research in familial risk contexts (early-onset neurodegeneration, familial cardiovascular disease). Post-Acute Illness Senolytic Recovery: Severe illness (COVID-19, sepsis, major surgery, ICU stays) induces senescence burden; senolytic treatment during recovery period may improve outcomes. Emerging research; not standard practice. Senolytics and Cancer: Complex. Senescence can be protective against cancer (cell cycle arrest in DNA-damaged cells); premature senolytic elimination could theoretically increase cancer risk. Counterargument: chronic senescence burden contributes to tumor microenvironment dysfunction; appropriate senolytic use may reduce cancer risk. Current evidence does not clarify net effect. Use with awareness; avoid in active cancer except under oncology direction. Longitudinal Data Collection: Advanced users benefit from systematic outcome tracking: wearable devices (HRV, sleep, activity, cardiovascular metrics); patient-reported outcome measures; periodic formal functional assessments; biomarker panels; subjective well-being journaling. Contribute to evolving knowledge base. Patient Advocacy Groups: Engagement with longevity medicine community: SENS Research Foundation, Buck Institute programs, Methuselah Foundation, academic medical centers with aging programs, patient advocacy organizations for specific conditions. Ethical Framework: Advanced senolytic use operates at the frontier of evidence-based medicine and investigational medicine. Clear documentation of informed consent, off-label use rationale, monitoring plan, and outcome tracking. Appropriate humility about limitations of evidence base. Ongoing reassessment as evidence evolves. Disclosure: This educational content describes practices at the cutting edge of longevity medicine. Individual decisions require physician partnership, careful risk-benefit analysis, and awareness of evolving evidence base. Dasatinib is prescription-only with substantial side effect profile; casual use is not appropriate.
Commonly Stacked With
Dasatinib combines with complementary compounds primarily in the senolytic paradigm, where multi-agent targeting of senescence-associated anti-apoptotic pathways (SCAPs) produces broader efficacy than single agents. Dasatinib + Quercetin (D+Q — Foundational Senolytic Combination): The original and most-studied senolytic combination. Dasatinib targets SRC family kinases and ephrin receptors in senescent cells; quercetin targets PI3K/AKT, BCL-XL, and HIF-1α — complementary SCAP coverage. Clinical dosing in pilot trials: dasatinib 100 mg once daily × 2-3 consecutive days + quercetin 1000 mg once daily × 2-3 consecutive days (matched schedule). Quercetin form matters — most studies used standard quercetin dihydrate; some protocols use quercetin phytosome (Quercetin Phytosome / SR-Quercetin; improved bioavailability). Quercetin is OTC supplement, widely available, generally well-tolerated. Dasatinib + Fisetin: Alternative to quercetin in some protocols. Fisetin is a structurally similar flavonoid with complementary senolytic activity. Some practitioners use fisetin 1000-2000 mg/day concurrently or alternate between D+Q and fisetin monotherapy cycles. Fisetin has much better safety profile than dasatinib and can be used OTC without prescription. D+Q + Sirtuin/AMPK Activators: Building comprehensive longevity stack. D+Q pulsed senolytic + metformin 500 mg BID daily + NMN 500-1000 mg/day + berberine 500 mg TID + NAC 600 mg BID + Omega-3 2-3 g/day + Vitamin D + Magnesium + Creatine. Addresses multiple aging hallmarks simultaneously. D+Q + Rapamycin: Both target different longevity-relevant pathways. Dasatinib/Q is senolytic (removes senescent cells); rapamycin is mTORC1 inhibitor (reduces senescent cell accumulation and promotes autophagy). Some protocols combine: intermittent D+Q pulses + weekly rapamycin 3-6 mg. Mechanistically complementary; both require physician supervision. Common in advanced longevity protocols. Dasatinib + NAC: NAC provides glutathione support and may attenuate some dasatinib-related oxidative stress. Commonly co-administered during dasatinib exposure windows. Dasatinib + Periodic Fasting/Caloric Restriction: Some practitioners align D+Q pulses with fasting periods, theoretically leveraging autophagy induction and cellular stress response synergy. Research-level approach; not standard. Dasatinib + Exercise Program: Mouse data (Xu 2018 and others) suggest exercise amplifies senolytic effects through independent mechanisms (exercise-induced myokines affecting senescence, mechanical clearance of damaged tissue). Recommend maintaining regular exercise around dasatinib pulses. Dasatinib + Omega-3 Fatty Acids: Anti-inflammatory support during senolytic treatment; may reduce SASP rebound between cycles. Dasatinib + Antioxidant Stack: CoQ10, alpha-lipoic acid, PQQ — supporting mitochondrial function and antioxidant capacity during senolytic treatment. Dasatinib + Vitamin D/K2: Basic nutritional support; addresses common deficiencies in aging populations. Dasatinib + Telomerase Support (TA-65 etc.): Combining senolytic with telomere-support compounds is common in longevity protocols; mechanistic coherence (removing old/damaged cells + supporting replicative capacity of remaining cells). Evidence level preliminary. Cycling Protocols: Common schedule: D+Q for 2-3 consecutive days monthly or quarterly. Alternative: D+Q for 2-3 days every 6-8 weeks. Individual protocols vary based on clinical context, lab markers, and physician preference. More frequent than monthly dosing is generally not recommended due to dasatinib side effect accumulation. Medication Review Before Each Pulse: Before each D+Q cycle, review current medications for CYP3A4 inhibitors/inducers and gastric pH modifiers that would affect dasatinib exposure. Temporarily hold problematic medications during pulse days if possible. Hold antiplatelet agents during pulse days per clinical judgment. Indication-Specific Senolytic Combinations: Idiopathic Pulmonary Fibrosis (IPF) Protocol (Justice 2019 basis): Dasatinib 100 mg + quercetin 1000 mg daily × 3 consecutive days/week × 3 weeks. Research-level; standard IPF management (pirfenidone or nintedanib) remains primary. Diabetic Kidney Disease Protocol (Hickson 2019 basis): Dasatinib 100 mg + quercetin 1000 mg × 3 consecutive days, single cycle with follow-up. Adjunct to standard DKD management. General Aging/Healthspan: Monthly or quarterly pulsed D+Q with comprehensive longevity stack. Osteoarthritis (emerging indication): Intermittent D+Q with joint-specific protocols (PT, weight management, targeted interventions per joint). Pre-surgical Senolytic Clearance (emerging): Some practitioners administer D+Q 2-4 weeks before major elective surgery in older patients, aiming to reduce senescent cell burden and potentially improve perioperative outcomes. Preliminary/research-level. Post-Chemotherapy/Radiation Clearance: Senescent cell burden increases after cancer treatments; some oncologists are exploring senolytic treatment for improved post-treatment outcomes. Research-level; requires oncology coordination. Post-COVID Senescence (emerging): Severe COVID-19 may induce senescence burden; senolytic protocols under investigation for Long COVID. Aging-Associated Frailty: D+Q pulsed treatment for frail older adults; emerging evidence suggests functional improvements. Anti-Aging Longevity Practitioners' Approach: Many experienced longevity physicians now prefer fisetin-based senolytic protocols (fisetin 1000-2000 mg/day × 2-3 days monthly) over D+Q for most patients, given fisetin's vastly superior safety profile. Dasatinib-based protocols are reserved for patients with specific indications (e.g., elevated senescence biomarkers, specific senescence-driven conditions) where more aggressive intervention is justified. Combinations to AVOID: Dasatinib + strong CYP3A4 inhibitors (antifungals, macrolides, ritonavir); dasatinib + PPIs (during pulse days); dasatinib + warfarin without INR monitoring; dasatinib + other anticoagulants without bleeding risk discussion; dasatinib + known QTc-prolonging agents without ECG monitoring; dasatinib in patients with active bleeding, severe cardiac disease, pulmonary hypertension, or severe hepatic impairment. Coordination Requirements: Dasatinib senolytic use requires physician partnership. Coordinate with primary care, specialists managing comorbidities (cardiology, pulmonology, rheumatology as appropriate), and pharmacist for drug interaction review. Hospital/emergency care providers should be informed of recent dasatinib exposure. Informed Consent: Patients considering dasatinib-based senolytic protocols should have thorough informed consent discussion covering: off-label use status; limited clinical evidence base; substantial side effect profile; drug interaction considerations; monitoring requirements; cost implications (prescription required); alternatives including fisetin-based senolytic protocols.
Side Effects & Safety
Contraindications
Dasatinib has significant contraindications and extensive drug interactions that substantially limit appropriate use. **Absolute Contraindications**: Known hypersensitivity to dasatinib or tablet excipients (rare); Active severe bleeding or coagulopathy; Severe uncontrolled cardiac arrhythmia (particularly QTc-prolonging conditions); Active severe infection (relative — may proceed after resolution); Pregnancy (Category D; contraception required during use); Breastfeeding. **Strong Relative Contraindications (Essentially Exclude Use Without Specialist Guidance)**: Active bleeding disorder (hemophilia, severe thrombocytopenia, significant platelet dysfunction); Recent major bleeding event (GI bleed, intracranial hemorrhage, etc.); Uncontrolled cardiovascular disease (recent MI, unstable angina, severe heart failure); Pre-existing pulmonary arterial hypertension; Severe hepatic impairment (Child-Pugh C); Severe chronic kidney disease on dialysis (data limited); Active hepatitis B infection (risk of reactivation); Long QT syndrome or significant baseline QTc prolongation; History of severe dasatinib-associated adverse events; Severe platelet dysfunction from other causes (uremia, severe liver disease, etc.). **Relative Contraindications (Use With Caution and Specific Precautions)**: Controlled bleeding risk (on antiplatelet/anticoagulants — requires bleeding risk discussion and possibly temporary holding); Mild-moderate cardiovascular disease; Mild-moderate pulmonary disease; History of pleural effusion (regardless of cause); History of GI bleeding or peptic ulcer; Chronic PPI use (impaired absorption); Multiple medications with significant drug interactions; Elderly (>75) with multiple comorbidities; Pregnancy planning (stop before conception attempts); Active cancer not related to dasatinib indication (complex interaction potential with other cancer treatments); Elective surgery planned within 2-3 weeks. **Drug Interactions — COMPREHENSIVE LIST**: **Strong CYP3A4 Inhibitors (AVOID OR DOSE REDUCE)**: **Antifungals**: ketoconazole, itraconazole, posaconazole, voriconazole. **Macrolide antibiotics**: clarithromycin, telithromycin, erythromycin. **HIV/HCV antivirals**: ritonavir, cobicistat, lopinavir, nelfinavir, indinavir, saquinavir; elbasvir, grazoprevir (some combinations). **Other**: nefazodone, conivaptan; grapefruit juice regular consumption (>1 glass/day); Seville orange; pomelo; star fruit. If strong CYP3A4 inhibitor cannot be held, reduce dasatinib to 20-40 mg equivalent or use alternative senolytic. **Moderate CYP3A4 Inhibitors (CAUTION/DOSE ADJUSTMENT)**: **Calcium channel blockers**: diltiazem, verapamil. **Antifungals**: fluconazole (mild-moderate), isavuconazole. **Antibiotics**: some quinolones (ciprofloxacin mild). **Antiemetics**: aprepitant (chemotherapy antiemetic; moderate inhibitor). **Statins (as CYP3A4 inhibitors rather than substrates)**: atorvastatin (mild), lovastatin (mild-moderate). **Hormone replacement**: some progesterones. **CBD**: high-dose cannabidiol is moderate CYP3A4 inhibitor; clinically relevant at medical-grade doses. **Strong CYP3A4 Inducers (AVOID)**: **Antimicrobials**: rifampin, rifabutin, rifapentine. **Anticonvulsants**: phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine (moderate). **Antiviral**: efavirenz, etravirine, nevirapine. **Tuberculosis treatment**: isoniazid/rifampin combinations. **Herbal**: St. John's Wort. **Other**: enzalutamide, apalutamide, modafinil (moderate). If strong CYP3A4 inducer cannot be held, efficacy will be substantially reduced; consider alternative senolytic (fisetin). **Gastric pH Modifiers (CRITICAL ABSORPTION INTERACTION)**: **PPIs (ALL)**: omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole. Chronic PPI dramatically reduces dasatinib absorption (possibly >40% reduction). Strategy: hold PPI during pulse days; if cannot hold (severe reflux, active ulcer), use H2 blocker alternative with timing separation, or use alternative senolytic (fisetin). **H2 Blockers**: famotidine, cimetidine, ranitidine, nizatidine. Moderate absorption effect. Strategy: dasatinib 2-10 hours before H2 blocker. **Antacids**: calcium carbonate, magnesium hydroxide, aluminum hydroxide, sodium bicarbonate. Moderate effect. Strategy: separate by 2 hours. **Sucralfate**: can affect absorption; separate by 2 hours. **Bile acid sequestrants (cholestyramine, colestipol)**: separate by 4 hours. **QTc-Prolonging Agents**: **Class Ia/Ic antiarrhythmics**: quinidine, procainamide, disopyramide, flecainide, propafenone — additive QTc risk. **Class III antiarrhythmics**: amiodarone, sotalol, dofetilide, dronedarone, ibutilide — additive QTc risk plus amiodarone CYP3A4 inhibition. **Antipsychotics**: haloperidol, ziprasidone, quetiapine (modest), thioridazine, pimozide. **Antidepressants**: tricyclics (amitriptyline, imipramine, etc.), citalopram (moderate QTc effect), escitalopram. **Macrolides (many — already listed as CYP3A4 inhibitors)**: also additive QTc. **Fluoroquinolones**: levofloxacin, moxifloxacin (more QTc), ciprofloxacin (less). **Antiemetics**: ondansetron, granisetron (mild). **Others**: methadone, pentamidine, some TCAs. Strategy: review ECG baseline; avoid combinations in patients with baseline QTc prolongation. **Anticoagulants**: **Warfarin**: additive bleeding risk; INR monitoring during dasatinib exposure; possible dose adjustment. **DOACs**: apixaban, rivaroxaban, dabigatran, edoxaban — additive bleeding risk; consider holding during pulse days if clinical situation allows. **Heparins/LMWH**: enoxaparin, dalteparin, fondaparinux, heparin — additive bleeding risk; avoid overlap when possible. **Antiplatelet Agents**: **Aspirin** (all doses including low-dose cardiovascular prophylaxis) — additive antiplatelet effect; bleeding risk consideration; some protocols hold 81 mg aspirin during pulse days. **P2Y12 inhibitors**: clopidogrel, prasugrel, ticagrelor — significant additive antiplatelet effect; bleeding risk; some protocols hold during pulse days. **Dipyridamole**, **cilostazol** — additive antiplatelet. **NSAIDs**: **All NSAIDs** (ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, ketorolac, etc.) — additive bleeding and GI effects; hold during pulse days and avoid for at least 3 days post-pulse when possible. **Acetaminophen acceptable** as NSAID alternative. **Other Kinase Inhibitors**: Combination with other TKIs (imatinib, nilotinib, bosutinib, ponatinib, sunitinib, sorafenib, etc.) is generally avoided in senolytic contexts; may be relevant in complex oncology cases. **Immunosuppressants**: tacrolimus, cyclosporine, sirolimus, everolimus — CYP3A4 interactions; monitor drug levels; avoid combinations when possible. **Hormone Replacement**: estrogens, progestins — generally compatible; some modest CYP3A4 interactions. **Contraceptives**: oral contraceptives generally compatible; injectable contraceptives no interaction. **Pregnancy Prevention**: women of reproductive potential on dasatinib must use reliable contraception during treatment. **Antidiabetic Agents**: insulin, sulfonylureas, metformin, GLP-1 agonists, SGLT2 inhibitors — generally compatible; monitor glucose. **Thyroid Hormone (Levothyroxine)**: generally compatible; some reports of thyroid dysfunction with dasatinib (monitor TFTs periodically). **Psychiatric Medications**: SSRIs, SNRIs — mild QTc considerations (particularly citalopram, escitalopram); additive bleeding risk with SSRIs; generally usable with monitoring. **Pain Management**: Opioids — generally compatible; fentanyl and some others CYP3A4 metabolized so exposure may be affected. **Inhaled Medications**: inhaled corticosteroids, bronchodilators — no significant interaction. **Topical Medications**: no significant systemic interactions. **Herbal Interactions**: **St. John's Wort (CYP3A4 inducer) — avoid**. **Goldenseal (CYP3A4 inhibitor) — caution**. **Kava — avoid (hepatotoxicity)**. **Ginkgo — additive bleeding**. **Garlic (high-dose) — additive bleeding**. **Ginger (high-dose) — additive bleeding**. **Ginseng — modest CYP3A4 effects; generally compatible**. **Milk thistle — generally compatible**. **Turmeric/Curcumin — compatible at typical supplemental doses; additive antiplatelet at high doses**. **Green tea extract (high dose)** — potential CYP3A4 effects. **Alcohol**: Avoid during and for 24 hours after pulse days. Moderate consumption between cycles acceptable. Heavy drinking should be addressed regardless of dasatinib use. **Tobacco**: Not a direct pharmacokinetic interaction but smokers have increased cardiovascular and pulmonary risk that compounds dasatinib risks. **Cannabis**: High-dose CBD is CYP3A4 inhibitor (relevant); THC has less interaction but may have cardiac effects at high dose. Generally minimize during pulse days. **Food**: Grapefruit juice (avoid during pulse). Regular balanced meals acceptable. Take with or without food. **Laboratory Test Effects**: Dasatinib does not typically interfere with common laboratory assays. May affect thyroid function tests modestly with chronic use. **Surgical Considerations**: Hold dasatinib at least 1 week before elective surgery; longer (2-3 weeks) if possible given platelet function effects. Emergency surgery: consider platelet transfusion for significant bleeding; discuss with hematology for management. **Dental Procedures**: Hold dasatinib at least 1 week before invasive dental procedures (extractions, implants, deep cleaning with significant bleeding); routine cleaning without bleeding generally acceptable. **Vaccinations**: Live vaccines generally avoided during oncologic TKI therapy; intermittent senolytic dosing may be more permissive but timing considerations important (e.g., receive vaccines at least 2 weeks before or 2 weeks after pulse). Inactivated vaccines generally acceptable. **Special Populations**: **Elderly (>65)**: Compatible with monitoring; higher comorbidity burden requires careful drug interaction review; dose reduction may be appropriate. **Frail elderly (>80)**: Consider alternative senolytics (fisetin) given better safety profile. **Renal Impairment**: No specific dose adjustment for mild-moderate; limited data severe. **Hepatic Impairment**: Dose reduction for moderate; avoid for severe. **Pregnancy**: Contraindicated. **Breastfeeding**: Contraindicated. **Pediatric Senolytic Use**: NOT appropriate outside specific trials. **Active Cancer**: Oncologic coordination essential. **Transplant Recipients**: Immunosuppressant interactions; specialist coordination. **HIV/HCV Patients**: Antiretroviral interactions; specialist coordination. **Regulatory Status**: Prescription-only globally. Off-label senolytic use requires licensed physician prescription. **Quality/Product**: Use only pharmacy-sourced product with prescription; avoid research-chemical sources. **Overdose**: Rare in senolytic context given intermittent dosing. Management: supportive care; monitor for cytopenias, bleeding, fluid retention, cardiac symptoms; no specific antidote. **Discontinuation**: Can be stopped abruptly without withdrawal. Senescent cell burden gradually increases post-discontinuation. **Symptoms Requiring Urgent Medical Attention**: GI bleeding (melena, hematemesis, hematochezia); severe fatigue with pallor; shortness of breath; chest pain; severe headache with neurologic symptoms; prolonged/heavy bleeding; severe abdominal pain; edema with weight gain; jaundice; severe rash with systemic symptoms; fever suggesting infection. **Final Assessment**: Dasatinib has one of the most extensive drug interaction and safety consideration profiles of any intervention commonly used in longevity medicine. Appropriate use requires complete clinical partnership. For many patients, [fisetin](/compound/fisetin) provides a substantially safer senolytic option that can be used OTC without the interaction complexity.
Additional Notes
Dasatinib dosing differs fundamentally between oncologic and senolytic applications. FDA-Approved Oncologic Dosing (for context): CML chronic phase first-line: 100 mg once daily continuously. CML accelerated/blast phase: 140 mg once daily or 70 mg BID. Ph+ ALL: 140 mg once daily or 70 mg BID. Dose adjustments for adverse events: CBC-guided reductions typically to 80 mg or 50 mg daily. Pediatric dosing: weight-based per oncology protocols. Senolytic Dosing (Off-Label): Not FDA-approved; evidence from pilot trials and off-label use: Standard Senolytic Dose: Dasatinib 100 mg once daily × 2-3 consecutive days (single pulse), combined with quercetin 1000 mg once daily × 2-3 days (matched schedule). Reduced Senolytic Dose (for sensitivity, elderly, frail): Dasatinib 50 mg × 2 days or 70 mg × 2 days. Cycle Frequency: Monthly (aggressive), every 6-8 weeks (moderate), quarterly (conservative maintenance). Most common: monthly to quarterly. Duration of Individual Pulse: 2 consecutive days is most common; 3 consecutive days as in Justice 2019 and Hickson 2019 trials; single day for first-time/cautious dosing. Timing: Morning with water; with or without food (food does not significantly affect absorption). Quercetin taken concurrently. Gastric pH Consideration (Critical): Dasatinib absorption is pH-dependent. Hold PPIs during and 12+ hours before pulse days. H2 blockers: separate by 10+ hours. Antacids: separate by 2 hours. If PPI cannot be held (severe GERD, active ulcer), absorption will be substantially impaired and efficacy reduced — consider alternative senolytic (fisetin) in such cases. Drug Interaction Check (Critical Before Each Pulse): Review for CYP3A4 inhibitors (antifungals, macrolides, HIV antivirals — AVOID or hold); CYP3A4 inducers (rifampin, anticonvulsants, St. John's Wort — AVOID); grapefruit/pomegranate juice — hold during pulse; other QTc-prolonging agents — ECG consideration; anticoagulants and antiplatelets — bleeding risk review. Quercetin Considerations: Standard quercetin dihydrate 1000 mg is the form used in pivotal trials. Alternative forms: Quercetin Phytosome (Quercefit) — improved bioavailability; may allow lower dose (e.g., 250-500 mg provides similar systemic exposure). SR-Quercetin (controlled-release) — smoother pharmacokinetics. Quercetin + bromelain — some combination products; primarily bromelain additive rather than quercetin-specific. Blood Level Monitoring: Dasatinib plasma levels can be measured (specialty labs); not routinely needed for intermittent senolytic dosing. Therapeutic drug monitoring more relevant for chronic oncologic use. Upper Dose: Recommended not to exceed 100 mg dasatinib per pulse day; 140 mg and higher doses (used in some oncologic contexts) produce substantially higher cumulative toxicity without clear senolytic benefit advantage. Alternative Senolytic Agents to Consider Instead: For patients unable to use dasatinib (drug interactions, comorbidities, bleeding risk, cost): Fisetin 1000-2000 mg × 2-3 days monthly — natural, OTC, better safety; emerging evidence base. Form/Product: Prescription dasatinib in 20, 50, 70, 80, 100, 140 mg tablets. 100 mg tablet is standard for senolytic use. Generic dasatinib widely available (2020+) at substantial cost reduction vs brand Sprycel. Quercetin: OTC in capsule (typically 500 mg per capsule; take 2 for 1000 mg dose). Reputable brands: Thorne, Pure Encapsulations, Life Extension, Jarrow, Doctor's Best, Solgar, NOW Foods. Storage: Dasatinib: original blister pack or pharmacy container; room temperature; protect from moisture and light. Quercetin: original container; room temperature; protect from light. Missed Dose During Pulse: If missed same day, take when remembered if >4 hours before bedtime. If missed and next day begins: do not double up; take scheduled dose of next day; consider extending pulse by one day if feasible or accept single-day effective exposure. Post-Pulse Considerations: No specific "washout" required. Return to normal medication schedule 24 hours after last pulse dose (can resume PPIs if held, NSAIDs if held, etc.). Continue chronic supplements uninterrupted. Monitoring Post-Pulse: Symptom review daily × 1 week; CBC at 7-14 days after first several pulses; less frequent with established tolerance. Lab Monitoring Cadence: Baseline: CBC, CMP, LFTs, coagulation, ECG, echo if indicated, HBV screening. Every 3 months × first year: CBC, CMP, LFTs, inflammatory markers. Every 6 months thereafter if stable: basic panel. Annually: ECG, comprehensive assessment. Response Assessment: Subjective well-being: daily journaling. Functional measures: baseline and 3-6 month intervals. Biomarkers: every 3-6 months. Duration of Senolytic Therapy: No established optimal duration. Some practitioners use finite courses (12-24 cycles over 1-2 years) then reassess. Others continue long-term maintenance (every 6-12 weeks indefinitely). Evidence for either approach is limited. Cost Reference: Generic dasatinib 100 mg: widely variable pricing; with insurance coverage, co-pays vary from $20-200 per tablet; without insurance/for cash pay, $50-500 per tablet at various pharmacies. Sprycel brand substantially higher. Mark Cuban Cost Plus Drug Company and similar low-cost pharmacies offer generic dasatinib at reduced pricing. Discussion with physician and pharmacist about cost optimization is appropriate. Quercetin: $15-30 per bottle for standard dihydrate; $30-50 for phytosome forms. Insurance Coverage: Off-label senolytic use typically NOT covered by insurance. Patients typically pay out-of-pocket. Some HSA/FSA accounts may cover with appropriate physician documentation. Legal Considerations: Dasatinib requires prescription in US and most jurisdictions. Obtaining from research-chemical sources is legally problematic and not recommended. Legitimate off-label prescription by licensed physician is legal; the decision to prescribe is the physician's professional judgment. Pharmacy Considerations: Some pharmacies may not stock dasatinib routinely; planning in advance is appropriate. Specialty pharmacies (CVS Caremark Specialty, Express Scripts Accredo, others) routinely handle TKIs and may be more experienced with storage/handling. International Considerations: Dasatinib availability and pricing varies by country. Some countries have more accessible generic dasatinib; others have different regulatory status. International travel with dasatinib: carry prescription documentation.
Frequently Asked Questions
What is the recommended Dasatinib dosage?
Dosage for Dasatinib varies by protocol. Consult a qualified healthcare provider.
How often should I take Dasatinib?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Dasatinib need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Dasatinib side effects?
Dasatinib has a substantial and well-characterized side effect profile from extensive oncologic use. Intermittent senolytic dosing reduces but does not eliminate these risks. **Common Side Effects in Chronic Oncologic Dosing (for context)**: Thrombocytopenia (>20% of patients, dose-related); neutropenia (15-25%); anemia (10-20%); fluid retention including pleural effusion (10-30%, higher with BID vs QD dosing), peripheral edema, ascites; diarrhea (20-30%); headache (20-30%); fatigue (20-30%); nausea (15-25%); rash (15-25%); musculoskeletal pain; elevated liver enzymes (5-15%). **Serious Side Effects in Oncologic Dosing**: Severe myelosuppression requiring dose interruption/reduction; pulmonary arterial hypertension (rare, potentially irreversible, requires monitoring); pleural effusion requiring thoracentesis; GI bleeding (uncommon but notable); QTc prolongation and rare torsades; rare severe skin reactions (Stevens-Johnson syndrome). **Side Effects in Senolytic Intermittent Dosing**: Lower absolute incidence but still notable. Most commonly reported in pilot trials and off-label use: Mild-moderate fatigue (30-50% of single-pulse exposures); GI upset — nausea, loose stools, abdominal discomfort (20-30%); headache (10-20%); transient myalgia/arthralgia (10-15%); easy bruising or minor bleeding (platelet function impairment; variable); transient fluid retention/edema (rare). **Rare But Reported in Senolytic Dosing**: GI bleeding (hematochezia, melena, hematemesis) — this is a notable concern given dasatinib's platelet inhibition; cases have been reported even in intermittent pulsed dosing. Pleural effusion — rare but reported with intermittent dosing. Atrial fibrillation — rare reports. Significant transaminase elevations. Severe headache with intracranial bleeding concerns. **Bleeding Risk Mechanism**: Dasatinib's SRC kinase inhibition affects platelet function independent of platelet count. Platelets express SRC family kinases involved in ADP/thromboxane/collagen-receptor signaling. Dasatinib-exposed platelets have impaired aggregation even at normal platelet counts. Intermittent dosing allows platelet function recovery between cycles (~2-4 weeks for full restoration) but within-cycle and shortly post-cycle bleeding risk is elevated. **Drug Interactions**: Extensive. **Strong CYP3A4 Inhibitors (AVOID or SUBSTANTIAL DOSE REDUCTION)**: ketoconazole, itraconazole, voriconazole, posaconazole (antifungals); clarithromycin, erythromycin, telithromycin (antibiotics); ritonavir, cobicistat, lopinavir, nelfinavir (HIV antivirals); nefazodone; grapefruit juice >1 glass/day; amiodarone (longer half-life interaction). **Moderate CYP3A4 Inhibitors (CAUTION/DOSE ADJUSTMENT)**: diltiazem, verapamil (CCBs); fluconazole; aprepitant; amiodarone (acute); imatinib; some statins. **Strong CYP3A4 Inducers (AVOID)**: rifampin, rifabutin; phenytoin, carbamazepine, phenobarbital (anticonvulsants); St. John's Wort; enzalutamide, apalutamide; modafinil (moderate inducer); efavirenz, nevirapine. **Gastric pH Agents (Critical Interaction)**: PPIs (omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole) — dramatically reduce dasatinib absorption with chronic use; avoid if possible; if required, use separation timing of 12+ hours (PPI morning, dasatinib evening). H2 blockers (famotidine, cimetidine, ranitidine, nizatidine) — moderate reduction; separate dasatinib from H2 blocker by at least 2 hours (ideally 10 hours). Antacids (calcium carbonate, magnesium hydroxide, aluminum hydroxide) — moderate reduction; separate by 2 hours. **Anticoagulants**: Warfarin — additive bleeding risk with platelet dysfunction; INR monitoring more frequent during dasatinib exposure windows. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — additive bleeding risk; consider holding during pulsed dosing. **Antiplatelet Agents**: Aspirin, clopidogrel, prasugrel, ticagrelor — additive antiplatelet effect; notable bleeding risk with combination; careful risk-benefit decision required. Some protocols hold antiplatelet during pulsed dosing. **NSAIDs**: Additive bleeding risk via GI effects and platelet effects; minimize NSAID use during and near dasatinib pulses. **SSRIs/SNRIs**: Mild additive bleeding risk; generally not contraindicated. **Other TKIs**: Combining dasatinib with other TKIs is generally avoided. **Cardiac Medications**: QTc-prolonging agents — additive QTc risk; monitor ECG. Amiodarone — complex interaction including QTc additive effect plus CYP3A4 inhibition. **Immunosuppressants**: Tacrolimus, cyclosporine, sirolimus, everolimus — complex CYP3A4 interactions; avoid or monitor closely. **Chemotherapy Agents**: Additive toxicity in oncologic contexts; complex coordination for comprehensive treatment plans. **Statins**: CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin) — potential increased exposure; prefer rosuvastatin or pravastatin during dasatinib exposure windows. **Food Interactions**: Grapefruit juice regular consumption — avoid during dasatinib exposure. Food does not substantially affect dasatinib absorption (can take with or without food). **Alcohol**: Minimize during dasatinib exposure windows due to additive GI irritation and bleeding risk. Moderate alcohol between cycles acceptable. **Pregnancy**: Category D (not recommended in pregnancy). Contraception required for women of reproductive potential during treatment and for appropriate interval after last dose. **Breastfeeding**: Do not breastfeed during dasatinib treatment. **Pediatric Use**: FDA-approved for pediatric Ph+ ALL and chronic-phase CML; pediatric senolytic use is NOT established and not appropriate outside specific clinical trials. **Elderly**: Standard dosing applies; watch for drug interactions given polypharmacy. **Renal Impairment**: No specific dose adjustment in mild-moderate renal impairment; data limited in severe. **Hepatic Impairment**: Use caution; dose adjustment may be needed. **Surgical Considerations**: Hold dasatinib at least 1 week before elective surgery; do not resume until bleeding risk acceptable (typically 1-2 weeks post-op). Emergency surgery: consider platelet transfusion if significant bleeding. **Myelosuppression Monitoring**: Even in intermittent senolytic dosing, baseline CBC before first pulse is essential. Repeat CBC 1 week after pulse is reasonable to identify unexpected cytopenias. **Liver Function Monitoring**: Baseline and periodic LFTs (ALT, AST, alkaline phosphatase, bilirubin). Hepatitis B reactivation has been reported with dasatinib; HBV screening in at-risk populations. **Cardiac Monitoring**: Baseline ECG for QTc; consider periodic ECG with chronic exposure. Echocardiogram for pulmonary pressure assessment with long-term or high-exposure dosing. **Product Quality/Source**: Dasatinib is prescription-only; legitimate sources are pharmacies with prescription (either brand Sprycel or generic dasatinib now available in most markets). Research-chemical-sourced dasatinib lacks quality assurance and is legally problematic in most jurisdictions. DO NOT purchase from unregulated sources. **Storage**: Room temperature, protected from humidity and light. Original container. **Discontinuation in Adverse Event**: Dasatinib should be held for any significant adverse event (bleeding, severe GI effects, cardiac symptoms, respiratory symptoms). Resumption requires clinical judgment and typically involves risk-benefit reassessment. **Overall Safety Assessment**: Dasatinib is a potent TKI with substantial adverse effect potential. Intermittent senolytic dosing has better safety profile than chronic oncologic dosing, but it is NOT a benign intervention. Appropriate for: physician-supervised use with monitoring; baseline and periodic labs; clear risk-benefit rationale; coordination with all prescribers. Not appropriate for: casual self-experimentation; use without baseline/monitoring labs; use in patients with bleeding diathesis, active cardiac or pulmonary disease, or complex medication regimens without careful drug interaction review.
Where can I buy Dasatinib?
Visit our vendor directory to find trusted sources for Dasatinib.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
